Brian Taylor Slingsby bought $3.5M of Mineralys Therapeutics (MLYS)

Executed Mar 13 2025, disclosed Apr 25 2025, 43 days later, against a two-business-day limit.

Value, as filed

$3.5M

259,259 sh × $13.50

Executed

Mar 13 2025

the trade date, as filed

Disclosed

Apr 25 2025

43 days after the trade · past the deadline

Return, 21 sessionsiFrom the disclosed entry session; derived

+15.7%

-6.4% from execution

Over the 21 trading sessions from the disclosed entry session (Apr 25 2025), the stock returned +15.7% (delay-adjusted); from the execution session (Mar 13 2025), -6.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

BS Brian Taylor Slingsby Director profile →

Brian Taylor Slingsby (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $43.4M of MLYS (1,000,000 sh × $43.35, as filed), executed Nov 20 2025.

The name

MLYS Mineralys Therapeutics, Inc. MLYS · Healthcare · 50 filings in 24 months ticker →

Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Brian Taylor Slingsby in MLYS

MLYSSALE Mineralys Therapeutics, Inc. $43.4M
1,000,000 sh × $43.35
Exec Nov 20 2025
Filed Nov 21 2025 · 5:30 PM ET